Arai Sally, Klingemann Hans-G
Section of Bone Marrow Transplant and Cell Therapy, RUSH-Presbyterian-St. Luke's Medical Center, Chicago, IL 60012, USA.
Arch Med Res. 2003 Nov-Dec;34(6):545-53. doi: 10.1016/j.arcmed.2003.07.002.
Peripheral blood stem cells have largely replaced bone marrow as the source of cells in autologous transplantation because of more rapid neutrophil and platelet recovery and faster immune reconstitution. Allogeneic peripheral blood stem cells similarly lead to faster hematologic recovery: however, their effects on graft-vs.-host disease, relapse, survival, and immune reconstitution have been less certain. Eight randomized trials have been published to date comparing the clinical outcomes of allogeneic-related donor bone marrow transplantation (BMT) vs. PBSCT and will be reviewed. In addition, comparisons between the two stem cell sources in unrelated donor transplantation and the increasingly utilized nonmyeloablative transplantation will be discussed.
由于中性粒细胞和血小板恢复更快以及免疫重建更快，外周血干细胞在很大程度上已取代骨髓成为自体移植的细胞来源。同种异体外周血干细胞同样能使血液学恢复更快：然而，它们对移植物抗宿主病、复发、生存及免疫重建的影响尚不太明确。迄今为止，已发表了八项随机试验，比较了同种异体相关供体骨髓移植（BMT）与外周血干细胞移植（PBSCT）的临床结果，并将进行综述。此外，还将讨论无关供体移植中两种干细胞来源之间的比较以及越来越常用的非清髓性移植。
